Biohaven is a healthcare company focused on developing innovative therapies for neurological diseases. Its core products include treatments for migraine and other central nervous system disorders. The company primarily generates revenue through the commercialization of its pharmaceutical products, with a significant emphasis on research and development to expand its product pipeline.
The investment profile of Biohaven is more aligned with growth investors due to its focus on innovative drug development and potential for future revenue generation. However, the high risk associated with its current financial performance and market volatility may deter conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept higher risk for potential returns.
| Fecha | Antes | Después | Razón |
|---|---|---|---|
| 2026-06-05 02:55 | Vender | Mantener | Weak fundamentals with mixed momentum signals. |
| 2026-06-03 03:32 | Mantener | Vender | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-28 02:36 | Vender | Mantener | High volatility and negative EPS raise concerns. |
| Fecha | Analista | Acción | Objetivo | Precio entonces |
|---|---|---|---|---|
| 2026-05-13 12:01 | Morgan Stanley | Objetivo reducido | 21 → 18 | 8.93 |
| 2026-03-04 11:41 | H.C. Wainwright | Objetivo reducido | — → 10 | 10.39 |
| 2026-03-03 19:43 | Leerink Partners | Actualizar | — → 15 | 10.67 |
